Afoxolaner (NexGard)

Afoxolaner is a novel antiparasitic medication belonging to the isoxazoline class, marketed under the brand name NexGard for use in dogs. This oral ectoparasiticide represents a significant advancement in flea and tick control, offering pet owners a convenient once-monthly chewable option that eliminates the mess and application concerns associated with topical products. Since its FDA approval for veterinary use, afoxolaner has become one of the most widely prescribed flea and tick preventives in canine medicine, valued for its efficacy, palatability, and reliable performance. The beef-flavored soft chewable formulation is readily accepted by most dogs as a treat, simplifying administration and improving compliance with monthly prevention protocols.

The mechanism of action of afoxolaner involves selective inhibition of gamma-aminobutyric acid-gated chloride channels and glutamate-gated chloride channels in the nervous systems of invertebrates, including fleas and ticks. These ligand-gated chloride channels are essential for normal nerve impulse transmission in arthropods. When afoxolaner binds to these receptors, it causes uncontrolled neuromuscular activity leading to paralysis and death of the parasites. Importantly, the binding sites targeted by afoxolaner are structurally different in mammals compared to invertebrates, providing a significant margin of safety for dogs. After oral administration, afoxolaner is rapidly absorbed and distributed throughout the body, reaching concentrations in the bloodstream and tissues that are lethal to fleas and ticks when they feed on the treated dog.

NexGard is available as beef-flavored soft chewable tablets in four size ranges designed to provide accurate dosing across the wide range of dog sizes. The formulations are color-coded and labeled by weight range, with products available for dogs 4 to 10 pounds, 10.1 to 24 pounds, 24.1 to 60 pounds, and 60.1 to 121 pounds. For dogs exceeding 121 pounds, an appropriate combination of chewables is prescribed to achieve the correct total dose. Each chewable delivers the active ingredient at a minimum dose of 2.5 milligrams per kilogram of body weight. The soft, palatable formulation has high acceptance rates, with most dogs readily consuming the chewable when offered as a treat or mixed with a small amount of food.

Afoxolaner has demonstrated an excellent safety profile in clinical trials and post-market surveillance when used according to label directions in healthy dogs. The product is approved for use in dogs and puppies eight weeks of age and older weighing at least four pounds. As with all medications, individual dogs may respond differently, and some dogs should not receive isoxazoline products due to specific health conditions. Veterinary guidance is essential for determining whether afoxolaner is appropriate for each individual dog, establishing the correct product size based on current body weight, and monitoring for efficacy and any potential adverse effects throughout treatment.

The primary indication for afoxolaner is the treatment and prevention of flea infestations caused by Ctenocephalides felis, the cat flea that is paradoxically the most common flea species affecting dogs. Afoxolaner begins killing fleas within four hours of administration and achieves greater than 99 percent efficacy against existing flea infestations within twenty-four hours. By killing adult fleas before they can lay eggs, afoxolaner helps break the flea life cycle and prevents environmental infestation in the home. This rapid and sustained flea-killing activity makes afoxolaner an excellent choice for both treating active infestations and preventing reinfestation in dogs living in areas with flea pressure.

Tick prevention and treatment represents another major indication for afoxolaner use. The medication has demonstrated efficacy against multiple tick species including the American dog tick (Dermacentor variabilis), black-legged tick or deer tick (Ixodes scapularis), brown dog tick (Rhipicephalus sanguineus), and Lone Star tick (Amblyomma americanum). Ticks are killed within forty-eight hours of attachment, helping reduce the risk of tick-borne disease transmission. For dogs in endemic areas for Lyme disease, ehrlichiosis, Rocky Mountain spotted fever, and other tick-transmitted infections, consistent monthly afoxolaner administration provides important protection. The oral route of administration ensures full-body distribution of the active ingredient, eliminating concerns about incomplete coverage that can occur with topical products.

Prevention of flea allergy dermatitis represents an important secondary indication for afoxolaner. Flea allergy dermatitis is the most common dermatological condition in dogs, caused by hypersensitivity to proteins in flea saliva that are injected during feeding. Even a single flea bite can trigger intense itching and skin inflammation in sensitized dogs. By killing fleas rapidly before they have the opportunity for prolonged feeding, afoxolaner helps prevent the allergic reaction in susceptible dogs. For dogs with established flea allergy dermatitis, consistent monthly treatment helps eliminate ongoing flea exposure and allows the skin to heal.

Afoxolaner is also indicated for treatment of demodectic mange caused by Demodex canis mites and sarcoptic mange caused by Sarcoptes scabiei mites when used at the standard monthly dose or at adjusted protocols as prescribed by the veterinarian. While not all isoxazoline products carry these indications on their labels, the class has demonstrated efficacy against these mites. Dogs with generalized demodicosis or sarcoptic mange may benefit from afoxolaner treatment as part of a comprehensive management plan developed by their veterinarian.

Veterinarians choose afoxolaner over alternative flea and tick products for various reasons including convenience of monthly oral dosing, high palatability improving owner compliance, full-body efficacy without concerns about topical product distribution, suitability for dogs that swim or bathe frequently, and lack of residue concerns for households with children who contact their pets. The rapid onset of action against fleas makes it valuable for quickly addressing active infestations. For multi-dog households, oral administration eliminates concerns about dogs grooming each other and ingesting topical products applied to housemates.

The dosing protocol for afoxolaner is straightforward, with the medication administered once monthly as a single oral dose at the minimum rate of 2.5 milligrams per kilogram of body weight. Accurate weight measurement is essential for selecting the appropriate product size, as underdosing may result in inadequate parasite control while excessive dosing increases medication cost unnecessarily. Veterinary staff typically weigh dogs at each wellness visit and can recommend the correct NexGard product size based on current body weight. For dogs whose weight falls at the boundary between product sizes, the veterinarian will advise on the appropriate choice based on whether weight gain or loss is anticipated.

NexGard chewables are available in four weight-based formulations to accommodate the wide size range of dogs. Dogs weighing 4 to 10 pounds receive a chewable containing 11.3 milligrams of afoxolaner. Dogs weighing 10.1 to 24 pounds receive a chewable containing 28.3 milligrams of afoxolaner. Dogs weighing 24.1 to 60 pounds receive a chewable containing 68 milligrams of afoxolaner. Dogs weighing 60.1 to 121 pounds receive a chewable containing 136 milligrams of afoxolaner. For dogs weighing more than 121 pounds, an appropriate combination of chewables is given to achieve the correct dose based on actual body weight.

Treatment with afoxolaner should continue monthly throughout the flea and tick season or year-round in areas with continuous parasite pressure. In many geographic regions, year-round prevention is recommended because mild winters allow fleas to survive and ticks can be active on any day when temperatures exceed freezing. Breaking the treatment cycle during perceived low-risk periods can result in flea infestation of the home environment or tick attachment with associated disease transmission risk. The veterinarian can advise on the appropriate duration and timing of treatment based on local parasite pressure and the individual dog's exposure risks.

Administration of afoxolaner is designed to be easy and convenient for pet owners. The beef-flavored soft chewable can be given with or without food, though administration with food may improve absorption in some dogs. Most dogs accept the chewable readily as a treat directly from the owner's hand. For dogs that are reluctant to accept the chewable, it can be hidden in a small amount of food or a treat pocket. The soft texture allows the chewable to be broken if necessary for administration, though the entire dose should be consumed. Owners should observe to ensure the dog chews and swallows the complete dose rather than spitting out portions.

If a dose is missed, the chewable should be administered immediately upon discovery of the missed dose, and then monthly dosing should continue from that date. There is no need to give a double dose to make up for a missed administration. If more than one month has elapsed between doses, the dog may be at risk for flea or tick infestation, and the owner should monitor for signs of parasites while resuming the regular prevention schedule. For dogs with heavy tick exposure that have missed doses, the veterinarian may recommend checking for attached ticks and considering testing for tick-borne diseases if warranted by clinical signs.

Consistent monthly administration throughout the recommended period is essential for maintaining effective flea and tick protection. The concentration of afoxolaner in the dog's bloodstream reaches peak levels shortly after dosing and then gradually declines over the following weeks. By the end of the dosing interval, levels remain above the threshold needed to kill parasites, but extending the interval beyond one month may result in gaps in protection. Setting a monthly reminder, such as a calendar alert or association with another monthly event, helps pet owners maintain consistent dosing. Many veterinary clinics offer reminder services to help clients stay on schedule with preventive medications.

Afoxolaner has demonstrated a favorable safety profile in clinical trials and extensive post-market use, with the majority of dogs tolerating the medication well when administered according to label directions. The FDA approval process included field safety studies evaluating hundreds of dogs, and ongoing adverse event monitoring continues to track the medication's safety in the general dog population. Understanding potential side effects helps pet owners monitor their dogs appropriately and report any concerns to their veterinarian promptly.

The most commonly reported side effects of afoxolaner in clinical studies were mild and transient gastrointestinal effects. Vomiting was observed in some dogs following administration, though this was typically mild and self-limiting without requiring treatment. Diarrhea and decreased appetite were also reported at low rates. These gastrointestinal effects are similar to those seen with many oral medications and often resolve within a day or two without intervention. Administering afoxolaner with food may help reduce the likelihood of stomach upset in dogs prone to gastrointestinal sensitivity.

Dermatological effects including dry or flaky skin, itching, and hair loss were reported in a small percentage of dogs receiving afoxolaner in clinical trials. In some cases, these signs may represent resolution of pre-existing flea allergy dermatitis rather than true medication side effects, as eliminating fleas allows allergic skin disease to heal. However, new onset of skin changes should be reported to the veterinarian to determine whether they represent a medication effect, flea allergy, or another dermatological condition requiring attention.

Neurological effects represent the most concerning potential adverse events associated with isoxazoline class medications, including afoxolaner. In rare cases, dogs have experienced neurological signs including muscle tremors, ataxia (loss of coordination), and seizures after receiving afoxolaner or other isoxazoline products. The FDA has issued a class-wide alert regarding potential neurological effects with isoxazoline products. Dogs with a history of seizures may be at higher risk, and the use of afoxolaner in these patients requires careful veterinary consideration of benefits and risks. Owners should seek immediate veterinary attention if their dog experiences tremors, uncoordinated movement, or seizures after taking afoxolaner.

Additional reported adverse events include lethargy, decreased activity, and changes in behavior in some dogs. As with neurological effects, these reports are uncommon relative to the large number of dogs receiving the medication. Any persistent behavioral changes or concerning symptoms should be reported to the veterinarian for evaluation. The veterinarian can help determine whether observed effects are related to the medication, coincidental, or indicative of another health issue requiring attention. Most dogs complete monthly afoxolaner treatment without experiencing any notable adverse effects.

Afoxolaner is contraindicated in dogs with known hypersensitivity to afoxolaner or other isoxazoline class medications. Dogs that have experienced allergic reactions to NexGard or similar products such as fluralaner, sarolaner, or lotilaner should not receive afoxolaner. Signs of hypersensitivity reaction may include facial swelling, hives, difficulty breathing, or severe skin reactions. If a dog has experienced any concerning reaction to an isoxazoline product, the veterinarian should be informed so alternative flea and tick prevention options can be considered.

Dogs with a history of seizures represent a population requiring special consideration before prescribing afoxolaner. The FDA has identified potential neurological adverse events, including seizures, associated with the isoxazoline class of medications. While many dogs with controlled epilepsy have used isoxazoline products without incident, the decision to prescribe afoxolaner to a dog with seizure history should involve careful discussion between the veterinarian and pet owner regarding potential risks and benefits. Alternative flea and tick prevention methods may be more appropriate for dogs with poorly controlled seizures or those who experience breakthrough seizures on anticonvulsant medication.

Afoxolaner is not approved for use in puppies under eight weeks of age or dogs weighing less than four pounds. The safety and efficacy of the medication in these very young or very small dogs has not been established through clinical trials. Puppies under eight weeks are still developing, and their ability to metabolize medications may differ from adult dogs. Very small dogs present dosing challenges as the smallest available product size may still exceed optimal dosing for their body weight. Alternative parasite prevention strategies should be discussed with the veterinarian for puppies not yet eligible for afoxolaner treatment.

Breeding, pregnant, and lactating dogs represent populations where afoxolaner use requires veterinary guidance. The medication has not been evaluated specifically for safety in breeding males, pregnant females, or lactating females and their nursing puppies. While no specific adverse effects have been documented in these populations, the lack of safety data means the decision to use afoxolaner should be made with awareness of this limitation. Pet owners planning to breed their dogs should discuss flea and tick prevention options with their veterinarian to determine the most appropriate approach for their situation. Complete disclosure of any health conditions, medications, and reproductive status helps the veterinarian make informed recommendations about afoxolaner suitability.

Pet owners should inform their veterinarian about all medications, supplements, and treatments their dog receives before beginning afoxolaner therapy. While afoxolaner has relatively few documented drug interactions, comprehensive medication disclosure allows the veterinarian to identify any potential concerns and adjust treatment plans appropriately. This includes prescription medications, over-the-counter products, herbal supplements, and any other flea, tick, or parasite prevention products the dog may be receiving.

Concurrent use of multiple antiparasitic products may be prescribed intentionally when comprehensive parasite coverage is desired, but should only occur under veterinary guidance. For example, a dog may receive afoxolaner for flea and tick prevention while also taking a heartworm preventive containing ivermectin or milbemycin oxime. These combinations are generally considered safe and are commonly prescribed. However, using multiple products with overlapping activity against the same parasites increases medication cost and exposure without additional benefit, and should be avoided unless specifically recommended by the veterinarian.

Dogs receiving anticonvulsant medications for seizure disorders represent a population where potential interactions or additive effects warrant consideration. While specific pharmacokinetic interactions between afoxolaner and anticonvulsants have not been documented, the potential for neurological adverse events with isoxazoline products may be of concern in dogs with seizure disorders. The veterinarian may want to monitor seizure control more closely when starting afoxolaner in epileptic dogs, or may recommend alternative flea and tick prevention methods for dogs with poorly controlled seizures.

Afoxolaner is metabolized primarily by the liver, and dogs with hepatic disease may potentially have altered drug processing. While clinical studies have not specifically evaluated afoxolaner in dogs with liver disease, veterinary assessment of liver function may be appropriate for dogs with known hepatic compromise before prescribing the medication. Similarly, dogs receiving medications known to affect liver enzyme activity should have potential interactions considered, though specific clinically significant interactions have not been documented with afoxolaner.

Monitoring for interactions involves observing the dog for expected medication effects and any unexpected symptoms that might indicate drug interactions or additive effects. Pet owners should report any concerns to the veterinarian, including changes in behavior, appetite, activity level, or any new symptoms that develop after starting afoxolaner or adding new medications to the dog's regimen. Good communication between pet owners and veterinary staff helps ensure that any potential interactions are identified and managed appropriately.

Standard precautions for afoxolaner use include accurate weight-based dosing, adherence to the monthly administration schedule, and monitoring for efficacy and adverse effects. Ensuring the correct product size is selected based on current body weight prevents underdosing that could result in treatment failure or overdosing that wastes medication unnecessarily. Weight should be rechecked periodically, especially in growing puppies, as product size may need adjustment as the dog's weight changes. Following the monthly dosing schedule maintains protective drug levels throughout the treatment period.

The FDA has issued a class-wide alert regarding potential neurological adverse events associated with isoxazoline products, including afoxolaner. These events include muscle tremors, ataxia, and seizures, and have been reported in some dogs, including dogs with no prior seizure history. While these events appear to be rare relative to the millions of doses administered, pet owners should be aware of this potential and monitor their dogs after administration. Dogs that experience neurological signs should receive immediate veterinary attention. For dogs with pre-existing seizure disorders, the veterinarian will weigh the benefits of effective flea and tick protection against potential risks when determining whether afoxolaner is appropriate.

Environmental considerations for afoxolaner use differ from those for topical products since the medication is administered orally rather than applied to the skin. There are no residue concerns for households with children, and dogs can be bathed, swim, or be groomed without affecting medication efficacy. However, the chewable tablets should be stored safely away from children and other pets to prevent accidental ingestion. The beef-flavored formulation may be attractive to dogs, and accidental consumption of multiple tablets could result in overdose. Keeping medication in its original packaging in a secure location prevents unintended access.

Monitoring for efficacy involves observing the dog for signs of flea or tick infestation that would indicate treatment failure. While afoxolaner is highly effective, no medication provides one hundred percent protection in all situations. Dogs should be checked periodically for fleas or ticks, particularly during peak season or after known exposure. Finding parasites on a treated dog may indicate a heavy environmental challenge, resistance issues, or missed doses. The veterinarian can help troubleshoot persistent parasite problems and may recommend environmental treatment or other interventions.

Special populations requiring additional consideration include senior dogs, dogs with chronic illness, and dogs receiving multiple medications. While afoxolaner is generally well tolerated in older dogs, age-related changes in organ function may affect drug metabolism. Dogs with chronic conditions should have their overall health status evaluated when making treatment decisions. Performance dogs, working dogs, and dogs in breeding programs may have specific needs that influence product selection. Open communication with the veterinarian about the dog's lifestyle, health status, and any concerns helps ensure that flea and tick prevention is tailored appropriately to each individual patient.

Proper storage of afoxolaner chewables maintains medication quality and prevents accidental ingestion by children or pets. NexGard should be stored at controlled room temperature between 68 and 77 degrees Fahrenheit, with excursions permitted between 59 and 86 degrees Fahrenheit as may occur during normal household temperature fluctuations. Extreme temperatures should be avoided, as heat or freezing could potentially affect the product's integrity or palatability. The medication should be kept in a dry location away from excessive humidity that could affect the soft chewable formulation.

NexGard chewables should remain in their original blister packaging until ready for administration. The blister packaging protects individual doses from moisture and oxidation while clearly identifying the product and weight class. Each chewable is individually packaged, reducing the risk of accidental consumption of multiple doses. The packaging displays the product name, active ingredient concentration, and weight range for the enclosed tablets, allowing verification that the correct product is being administered to the correct dog.

Safe storage location is particularly important for afoxolaner because the beef-flavored formulation is designed to be palatable to dogs. Dogs may seek out and consume the medication if given access, potentially resulting in significant overdose if multiple tablets are ingested. Storage should be in a location inaccessible to pets, such as a locked cabinet, high shelf, or closed medicine storage container. In households with multiple dogs, products should be clearly labeled or organized to prevent administration of the wrong size tablet to the wrong dog.

Disposal of unused or expired afoxolaner should follow local guidelines for pharmaceutical disposal. Expired medication may have reduced efficacy and should not be administered to dogs. Many communities offer pharmaceutical take-back programs that accept both human and veterinary medications. If take-back programs are unavailable, the medication can typically be mixed with an undesirable substance such as coffee grounds or cat litter, placed in a sealed container, and disposed of in household trash. Empty blister packaging can be disposed of according to normal recycling guidelines after ensuring no medication residue remains. The veterinarian or pharmacist can provide specific guidance on proper disposal methods in your area.

Afoxolaner can be used in dogs of all breeds, as the medication is not affected by breed-specific genetic variations that impact some other antiparasitic drugs. Unlike ivermectin and related medications that can cause severe toxicity in dogs with the MDR1 gene mutation, afoxolaner works through a different mechanism that does not involve the P-glycoprotein transport system affected by MDR1. This means that herding breeds including Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and related breeds can safely receive afoxolaner at standard doses for flea and tick prevention. The isoxazoline class provides an important alternative for these breeds when other antiparasitic options may carry increased risk.

While breed-specific drug sensitivities are not a concern with afoxolaner, the potential for neurological adverse events applies across all breeds. The FDA alert regarding seizures and other neurological effects with isoxazoline products does not identify specific breeds at higher risk. Dogs of any breed with a history of seizures or neurological conditions should be evaluated individually before prescribing afoxolaner. Breeds with known predisposition to epilepsy, such as Belgian Tervurens, Shetland Sheepdogs, Beagles, and several others, should have their seizure history thoroughly evaluated and discussed before starting isoxazoline therapy.

Size considerations are primarily relevant for product selection rather than safety concerns. Toy and small breeds must be accurately weighed to ensure the appropriate product size is selected, as the smallest available NexGard contains a minimum dose designed for dogs weighing at least four pounds. Very small dogs at the low end of the weight range should have their weight confirmed before each refill, particularly growing puppies that may cross into the next weight category. Giant breeds exceeding 121 pounds require combination dosing with multiple tablets to achieve the correct dose based on actual body weight, with specific guidance from the veterinarian on appropriate product combination.

Age considerations span all breeds and influence afoxolaner eligibility and monitoring. Puppies must be at least eight weeks of age and weigh at least four pounds before starting NexGard treatment. Growing puppies should have their weight monitored regularly, as the appropriate product size may change as they grow. Senior dogs may have age-related changes in metabolism that could affect drug processing, though afoxolaner is generally well tolerated in older dogs. Dogs of any age with concurrent health conditions should have their overall status considered when making flea and tick prevention decisions. The veterinarian can help determine whether afoxolaner is the most appropriate choice based on the individual dog's breed, age, size, and health status.

Within the isoxazoline class of oral ectoparasiticides, several alternatives to afoxolaner exist with similar mechanisms of action but different dosing intervals and additional label claims. Fluralaner, marketed as Bravecto, provides twelve weeks of flea and tick protection from a single dose and is available in both oral and topical formulations. Sarolaner, sold as Simparica and in combination products, offers monthly protection with additional claims against certain mite species. Lotilaner, marketed as Credelio, is another monthly oral option with similar efficacy against fleas and ticks. The choice among isoxazoline products often depends on owner preference for dosing frequency, the specific parasites of concern, and individual dog tolerance.

Non-isoxazoline alternatives for flea and tick prevention include both oral and topical options working through different mechanisms. Spinosad, available as Comfortis, provides monthly oral flea control but does not protect against ticks. Topical products containing fipronil, permethrin, or other active ingredients offer alternatives for owners preferring external application or for dogs that cannot receive isoxazoline products. Collars containing active ingredients such as flumethrin and imidacloprid provide extended-release flea and tick protection lasting several months. Each alternative has advantages and limitations that the veterinarian can discuss when determining the most appropriate choice for each dog.

Combination products that include afoxolaner alongside other active ingredients provide broader parasite spectrum coverage in a single product. NexGard SPECTRA combines afoxolaner with milbemycin oxime to provide protection against fleas, ticks, heartworm, and intestinal parasites in one monthly chewable. This combination approach simplifies parasite prevention protocols for pet owners while ensuring comprehensive protection. The decision to use a combination product versus separate products depends on the dog's specific parasite exposure risks, existing prevention protocols, and owner preference for simplified dosing versus targeted treatment.

Complementary approaches to flea and tick control may be recommended alongside afoxolaner for dogs with heavy parasite exposure or environmental infestation. Environmental treatment of the home and yard can reduce parasite populations and decrease reinfestation pressure. Regular grooming and inspection helps identify parasites early. For dogs with flea allergy dermatitis, additional skin treatments may be needed alongside flea prevention to manage allergic symptoms. The veterinarian can develop a comprehensive parasite prevention plan that may include afoxolaner as one component of an integrated approach tailored to each dog's exposure risks and health needs.